Physician profile
Sophy Yu
NPI 1861162497
$4,790.68
in general payments reported to CMS, 2019-2025
19 companies · $2,951 in 2025
The $2,951 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,839 · 2025: $2,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.68 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,275.60 | 2025 | Opzelura, Opzelura |
| Abbvie INC. | $563.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $521.86 | 2024-2025 | |
| Leo Pharma INC. | $356.75 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $330.74 | 2025 | Tremfya |
| Genzyme Corporation | $329.92 | 2024-2025 | |
| Pfizer INC. | $315.28 | 2024-2025 | |
| Dermavant Sciences, INC. | $250.75 | 2024 | Vtama |
| Amgen INC. | $191.63 | 2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $177.61 | 2024-2025 | Zoryve |
| Botanix Sb INC | $110.53 | 2025 | Sofdra |
| Ucb, INC. | $96.64 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $74.78 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $67.88 | 2024-2025 | |
| Lilly USA, LLC | $31.57 | 2025 | Ebglyss |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.39 | 2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $27.12 | 2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $22.78 | 2024 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $17.76 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sophy Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.